In humans, OX40 expression is higher in Tregs isolated from inflammatory sites such as tumors compared to Tregs in the peripheral blood [46], which imply that α-OX40 treatment is a reasonable approach in terms of immune-related side effects in sites other than the tumor. The gene discussed is TNFRSF4; the disease is neoplasm.